2001 Chronic Pain Clinical Trials Treatment 
Cannabis Law Report
AUGUST 2, 2021
Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug. ” About The Study.
The Cannigma
JANUARY 13, 2023
8 A 2018 animal study using THC on rats concluded that “THC reduces migraine-like pain when administered at the right dose” and there is “anecdotal evidence for the use of cannabinoids as a treatment for migraine in humans and implicate the CB1 receptor as a therapeutic target for migraine.” headaches per month.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.
Cannabis Law Report
NOVEMBER 24, 2021
Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). Conclusions.
Cannabis Law Report
OCTOBER 17, 2019
Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. Cannabis has been legal for medical purposes in Canada since 2001, with several iterations of regulation and legislation shaping the industry over the years.
Expert insights. Personalized for you.
105 
Let's personalize your content